Description: IGCPharma revolutionizing the Future of Alzheimer´s care
Our drug candidate, IGC-AD1, has shown promising results in treating agitation in Alzheimer’s patients.
With no known cure, our formulations have the potential to change lives
Americans with Alzheimer’s disease in 2022